These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dopaminergic induced changes in cognitive and motor processing in Parkinson's disease: an electrophysiological investigation. Prasher D; Findley L J Neurol Neurosurg Psychiatry; 1991 Jul; 54(7):603-9. PubMed ID: 1895125 [TBL] [Abstract][Full Text] [Related]
7. Step initiation in Parkinson's disease: influence of levodopa and external sensory triggers. Burleigh-Jacobs A; Horak FB; Nutt JG; Obeso JA Mov Disord; 1997 Mar; 12(2):206-15. PubMed ID: 9087979 [TBL] [Abstract][Full Text] [Related]
8. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group. Wolters EC; Horstink MW; Roos RA; Jansen EN Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204 [No Abstract] [Full Text] [Related]
10. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease. Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794 [No Abstract] [Full Text] [Related]
11. Comparison of motor response to apomorphine and levodopa in Parkinson's disease. Kempster PA; Frankel JP; Stern GM; Lees AJ J Neurol Neurosurg Psychiatry; 1990 Nov; 53(11):1004-7. PubMed ID: 2283512 [TBL] [Abstract][Full Text] [Related]
12. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Block G; Liss C; Reines S; Irr J; Nibbelink D Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028 [TBL] [Abstract][Full Text] [Related]
13. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329 [TBL] [Abstract][Full Text] [Related]
14. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Facca A; Sanchez-Ramos J Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153 [No Abstract] [Full Text] [Related]
16. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication. Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578 [TBL] [Abstract][Full Text] [Related]
17. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Zappia M; Montesanti R; Colao R; Branca D; Nicoletti G; Aguglia U; Quattrone A Mov Disord; 1997 Jan; 12(1):103-6. PubMed ID: 8990062 [TBL] [Abstract][Full Text] [Related]
18. Effect of Levodopa + Carbidopa on the Laryngeal Electromyographic Pattern in Parkinson Disease. Noffs G; de Campos Duprat A; Zarzur AP; Cury RG; Cataldo BO; Fonoff E J Voice; 2017 May; 31(3):383.e19-383.e23. PubMed ID: 27839704 [TBL] [Abstract][Full Text] [Related]
19. Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations. Benetello P; Furlanut M; Zara G; Baraldo M; Hassan E Eur Neurol; 1993; 33(1):69-73. PubMed ID: 8440292 [TBL] [Abstract][Full Text] [Related]